Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02412813
Other study ID # 13-4050-05
Secondary ID
Status Withdrawn
Phase N/A
First received March 5, 2015
Last updated March 8, 2016
Start date January 2016
Est. completion date April 2025

Study information

Verified date March 2016
Source Smith & Nephew, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, multi-center, metal hypersensitivity study comparing OXINIUM and cobalt chrome femoral components in subjects with failed total knee arthroplasty (TKA).


Description:

A total of 230 subjects will be randomized (1:1) to receive either an OXINIUM or cobalt chrome femoral components as part of their LEGION revision procedure. The objective of this study is to assess a lower serum metal ion concentration level in at least one of the three major mLTTs (Co, Cr or Ni) over 5 years in subjects receiving OXINIUM versus Cobalt Chrome femoral components as part of the LEGION Revision Total Knee System.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Subject is skeletally mature

- Subject is willing to sign and date an IRB/EC approved consent form

- Subject is a candidate for a revision knee replacement

- Subject has met an acceptable preoperative medical clearance and is free or treated for cardiac, pulmonary, hematological, infection, or other conditions that would pose excessive operative risk

- Subject agrees to adhere to the 10-year study visit schedule

Exclusion Criteria:

- Subject with a known metal hypersensitivity

- Subject requires a known bilateral revision TKA

- Subject has severe pronation of the ipsilateral foot or any other relevant clinical condition contributing to abnormal ambulation

- Subject has active infection or sepsis (treated or untreated)

- Subject with an immunosuppressive disorder

- Subject has presence of malignant tumor, metastatic, or neoplastic disease

- Subject has conditions that may interfere with the TKA survival or outcome (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease)

- Subject has had intra-articular corticosteroid therapy (or any other intra-articular therapy) in the study knee within 3 months of study enrollment

- Subject has inadequate bone stock to support the device and would require significant augmentation to correct the joint Female subject is of child-bearing age and unwilling to use an approved method of contraception

- Subject has an emotional or neurological condition that would pre-empt their ability or willingness to comply with the study

- Subject is severely overweight (BMI>40)

- Subject is currently enrolled in another investigational drug, biologic, or device study or has been treated with an investigational product in the past 30 days

- Subject is facing current or impending incarceration

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
LEGION OXINIUM
Investigational Group
LEGION Cobalt Chrome
Control Group

Locations

Country Name City State
Canada Orthopaedic Innovation Centre Winnipeg Manitoba
United States Rothman Institute Egg Harbor Township New Jersey
United States Columbia University Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Smith & Nephew, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major modified Lymphocyte Transformation Tests (Cobalt, Chromium and Nickel) measurements Metal hypersensitivity will be concluded if at least one of these three measurements is statistically significant 3,650 Days No
Secondary Minor modified Lymphocyte Transformation Tests (Aluminum, Iron, Molybdenum, Vanadium and Zirconium) changes in mean mLTTs serum concentration values from baseline to each subsequent assessment 3,650 Days No
Secondary Changes in mean serum bio-markers from baseline to each subsequent assessment 3,650 Days No
Secondary Skin lesion evaluation to measure hypersensitivity 3,650 Days No
Secondary Revision of LEGION Revision Knee System for any reason at each post-surgical assessment 3,650 Days No
Secondary Improves in mean 2011 Knee Society Score (2011 KSS) from baseline to each subsequent assessment 3,650 Days No
Secondary Anteroposterior, lateral and skyline knee views are assessed by radiographs 3,650 Days No
Secondary All adverse event reporting from surgery to 10 year post-surgery 3,650 Days No